313 related articles for article (PubMed ID: 17409404)
1. Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling.
Chng WJ; Kumar S; Vanwier S; Ahmann G; Price-Troska T; Henderson K; Chung TH; Kim S; Mulligan G; Bryant B; Carpten J; Gertz M; Rajkumar SV; Lacy M; Dispenzieri A; Kyle R; Greipp P; Bergsagel PL; Fonseca R
Cancer Res; 2007 Apr; 67(7):2982-9. PubMed ID: 17409404
[TBL] [Abstract][Full Text] [Related]
2. Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myélome.
Decaux O; Lodé L; Magrangeas F; Charbonnel C; Gouraud W; Jézéquel P; Attal M; Harousseau JL; Moreau P; Bataille R; Campion L; Avet-Loiseau H; Minvielle S;
J Clin Oncol; 2008 Oct; 26(29):4798-805. PubMed ID: 18591550
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma.
Richardson PG; Sonneveld P; Schuster MW; Irwin D; Stadtmauer EA; Facon T; Harousseau JL; Ben-Yehuda D; Lonial S; San Miguel JF; Cavenagh JD; Anderson KC
Br J Haematol; 2007 Jun; 137(5):429-35. PubMed ID: 17451408
[TBL] [Abstract][Full Text] [Related]
4. Upregulation of translational machinery and distinct genetic subgroups characterise hyperdiploidy in multiple myeloma.
Agnelli L; Fabris S; Bicciato S; Basso D; Baldini L; Morabito F; Verdelli D; Todoerti K; Lambertenghi-Deliliers G; Lombardi L; Neri A
Br J Haematol; 2007 Feb; 136(4):565-73. PubMed ID: 17367409
[TBL] [Abstract][Full Text] [Related]
5. Clinical and immunohistochemical features associated with a response to bortezomib in patients with multiple myeloma.
Dawson MA; Opat SS; Taouk Y; Donovan M; Zammit M; Monaghan K; Horvath N; Roberts AW; Prince HM; Hertzberg M; McLean CA; Spencer A
Clin Cancer Res; 2009 Jan; 15(2):714-22. PubMed ID: 19147779
[TBL] [Abstract][Full Text] [Related]
6. Expanding role of bortezomib in multiple myeloma: nursing implications.
Colson K; Doss DS; Swift R; Tariman J
Cancer Nurs; 2008; 31(3):239-49. PubMed ID: 18453881
[TBL] [Abstract][Full Text] [Related]
7. Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study.
Lee SJ; Richardson PG; Sonneveld P; Schuster MW; Irwin D; San Miguel JF; Crawford B; Massaro J; Dhawan R; Gupta S; Anderson KC
Br J Haematol; 2008 Nov; 143(4):511-9. PubMed ID: 18986387
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression.
Mateos MV; Hernández JM; Hernández MT; Gutiérrez NC; Palomera L; Fuertes M; Garcia-Sanchez P; Lahuerta JJ; de la Rubia J; Terol MJ; Sureda A; Bargay J; Ribas P; Alegre A; de Arriba F; Oriol A; Carrera D; García-Laraña J; García-Sanz R; Bladé J; Prósper F; Mateo G; Esseltine DL; van de Velde H; San Miguel JF
Haematologica; 2008 Apr; 93(4):560-5. PubMed ID: 18322252
[TBL] [Abstract][Full Text] [Related]
9. Weekly treatment with bortezomib for patients with recurrent or refractory multiple myeloma: a phase 2 trial of the Minnie Pearl Cancer Research Network.
Hainsworth JD; Spigel DR; Barton J; Farley C; Schreeder M; Hon J; Greco FA
Cancer; 2008 Aug; 113(4):765-71. PubMed ID: 18543319
[TBL] [Abstract][Full Text] [Related]
10. Ectopic cyclin D1 overexpression increases chemosensitivity but not cell proliferation in multiple myeloma.
Kuroda Y; Sakai A; Tsuyama N; Katayama Y; Munemasa S; Asaoku H; Okikawa Y; Nakaju N; Mizuno M; Ogawa K; Nishisaka T; Matsui H; Tanaka H; Kimura A
Int J Oncol; 2008 Dec; 33(6):1201-13. PubMed ID: 19020753
[TBL] [Abstract][Full Text] [Related]
11. Bortezomib in combination with conventional chemotherapeutic agents for multiple myeloma compared with bortezomib alone.
Min CK; Lee MJ; Eom KS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Lim J; Kim Y; Han K
Jpn J Clin Oncol; 2007 Dec; 37(12):961-8. PubMed ID: 18156171
[TBL] [Abstract][Full Text] [Related]
12. Bortezomib in combination with dexamethasone and subsequent thalidomide for newly-diagnosed multiple myeloma: a Chinese experience.
Zheng W; Wei G; Ye X; He J; Li L; Wu W; Shi J; Zhang J; Huang W; Xie W; Luo Y; Xue X; Lin M; Huang H; Cai Z
Leuk Res; 2009 Dec; 33(12):1615-8. PubMed ID: 19773080
[TBL] [Abstract][Full Text] [Related]
13. Expression of c-Kit isoforms in multiple myeloma: differences in signaling and drug sensitivity.
Montero JC; López-Pérez R; San Miguel JF; Pandiella A
Haematologica; 2008 Jun; 93(6):851-9. PubMed ID: 18443272
[TBL] [Abstract][Full Text] [Related]
14. Proteasome inhibition and multiple myeloma.
Kanagasabaphy P; Morgan GJ; Davies FE
Curr Opin Investig Drugs; 2007 Jun; 8(6):447-51. PubMed ID: 17621873
[TBL] [Abstract][Full Text] [Related]
15. Bortezomib in the front-line treatment of multiple myeloma.
Richardson PG; Mitsiades C; Schlossman R; Ghobrial I; Hideshima T; Munshi N; Anderson KC
Expert Rev Anticancer Ther; 2008 Jul; 8(7):1053-72. PubMed ID: 18588451
[TBL] [Abstract][Full Text] [Related]
16. A striking response to bortezomib in a patient with pleural localization of multiple myeloma.
Mangiacavalli S; Varettoni M; Zappasodi P; Pica G; Lazzarino M; Corso A
Leuk Res; 2009 Apr; 33(4):577-8. PubMed ID: 18842298
[No Abstract] [Full Text] [Related]
17. Clinical impact of bortezomib in frontline regimens for patients with multiple myeloma.
Manochakian R; Miller KC; Chanan-Khan AA
Oncologist; 2007 Aug; 12(8):978-90. PubMed ID: 17766658
[TBL] [Abstract][Full Text] [Related]
18. A SNP microarray and FISH-based procedure to detect allelic imbalances in multiple myeloma: an integrated genomics approach reveals a wide gene dosage effect.
Agnelli L; Mosca L; Fabris S; Lionetti M; Andronache A; Kwee I; Todoerti K; Verdelli D; Battaglia C; Bertoni F; Deliliers GL; Neri A
Genes Chromosomes Cancer; 2009 Jul; 48(7):603-14. PubMed ID: 19396863
[TBL] [Abstract][Full Text] [Related]
19. Gene expression profiling and multiple myeloma.
Shaughnessy J; Zhan F; Barlogie B; Stewart AK
Best Pract Res Clin Haematol; 2005; 18(4):537-52. PubMed ID: 16026736
[TBL] [Abstract][Full Text] [Related]
20. Utility of bortezomib retreatment in relapsed or refractory multiple myeloma patients: a multicenter case series.
Wolf J; Richardson PG; Schuster M; LeBlanc A; Walters IB; Battleman DS
Clin Adv Hematol Oncol; 2008 Oct; 6(10):755-60. PubMed ID: 18997666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
